CLLS (Cellectis) Likuiditas cepet

Cellectis S.A. (CLLS) specializes in developing innovative methods for combating tumors. This price trend illustrated below reflects the share price amid the scaling of TALEN technology to capture market share. The current indicator is 1.30. Business funding relies on partnership contracts, as there are no mature products. Significant threats include capital shortages, expensive production, and potential adverse bodily reactions.

The ratio is calculated by dividing the sum of cash and accounts receivable by current liabilities, intentionally excluding inventories. This metric determines the business's ability to instantly settle debts without liquidating stock. For Cellectis S.A. (CLLS), high liquidity is critical when monetizing gene-editing rights through licensing payments from pharma behemoths. The quick ratio trend reflects the company's financial stability in the face of rising operating expenses.